The year 2025 has been a significant one for the Indian pharmaceutical sector. It witnessed several novel launches, ...

FDA has taken steps to embrace AI in 2025, announcing in December that it will be providing agency staff with agentic AI ...

Entering 2026, India's pharmaceutical industry initiates a crucial five-year plan to evolve into an innovation hub, aiming ...

With GST reforms and Research Development Incentive (RDI) Scheme, the year 2025 has been a crucial turning point for Indian ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

For more than five years, pharma companies and PBMs have managed to avoid disclosing the actual prices of prescription drugs.

Managing a modern pharmaceutical supply chain is like building a house during a storm; it is no longer enough to ensure the ...

The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

Back in February, newly-confirmed Secretary of Health and & Human Services (HHS) Robert F. Kennedy Jr. promised to reverse decades of industry capture ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

India’s pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the ...